Slipping past the blood brain barrier: Research shows potential treatment for brain cancerAugust 23, 2005Saint Louis University findings are published in this week's PNAS online ST. LOUIS - A compound that kills cancer can sneak past the blood brain barrier, which protects the brain from foreign substances, to do its work in fighting a particularly invasive brain cancer, according to a new Saint Louis University animal study published in the Proceedings of the National Academy of Sciences Online Early Edition the week of Aug. 22. "The bottom line is, if you can get drugs into the brain, you can cure brain cancer," says William A. Banks, M.D., professor of geriatrics in the department of internal medicine and professor of pharmacological and physiological science at Saint Louis University School of Medicine and a member of the research team. The compound - JV-1-36 - is an antagonist of the hypothalamic growth hormone- releasing hormone, which has been found to cause cancerous tumors, such as malignant glioblastomas, to grow. The main known purposes of the hypothalamic growth hormone-releasing hormone usually are to trigger the hormone that makes children grow and affect how glucose is used in adults. Researchers found that the P-gp system, an extra guardian located at the blood brain barrier that usually keeps anticancer drugs out of the brain, intercepted some of the JV-1-36 that was injected into mice but let much of it pass into the brain to treat cancer. "The blood brain barrier is set up to very carefully patrol what it lets into the brain and what it keeps out. It makes these decisions based on the physicochemical properties," says Dr. Banks, who also is a staff physician at Veterans Affairs Medical Center in St. Louis. "Most of our drugs that fight cancers are toxic to cancer cells and to other cells, too. That's why the blood brain barrier locks them out of the brain." The research was done in collaboration with investigators at Tulane University School of Medicine in New Orleans, including Nobel Laureate Andrew V. Schally, Ph.D. Dr. Banks said the findings are promising because they show a way to get drugs into the brain to treat cancer. "There are times when there's a big difference between an animal model and the human condition. In terms of getting drugs across the blood brain barrier to fight cancer, there's not such a big difference. There's pretty much the same rules in any blood brain barrier - be it in a mouse or human." Laura Jaeger, the lead author of the study and a doctoral student in the department of pharmacological and physiological science at Saint Louis University, calls the findings "very positive and a good first step." Saint Louis University |
|||||||||||||||||||||
| Related Brain Cancer Current Events and Brain Cancer News Articles Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Toward a nanomedicine for brain cancer In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes. Experts warn over health check brain scans A new study has voiced concern about the growing market for brain screening tests, which people can buy as part of a general health MOT. Avastin dramatically improves response, survival in deadly recurrrent glioblastomas The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Computational Process Zeroes in on Top Genetic Cancer Suspects Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. NIH researchers identify key factor that stimulates brain cancer cells to spread Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). Anti-psychotic drugs could help fight cancer The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers. More Brain Cancer Current Events and Brain Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||